Eli Lilly and Company announced results from the Phase 3 monarchE trial evaluating Verzenio (abemaciclib) in combination with endocrine therapy for patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), node-positive, high-risk early breast cancer. The primary overall survival analysis showed that two years of adjuvant Verzenio plus endocrine therapy reduced the risk of death by 15.8% compared to endocrine therapy alone. The study also demonstrated sustained improvements in invasive disease-free survival and distant relapse-free survival. Safety findings were consistent with the known profile of Verzenio, with no new safety signals or delayed toxicities observed. These results were published in the Annals of Oncology and presented as a late-breaking oral session at the European Society for Medical Oncology (ESMO) Annual Meeting. The data are being submitted to regulatory health authorities globally.